NewAmsterdam Pharma Co N.V. (NAMS): Revenue

Annual figures by period end, from SEC filings.

$22.50M

Year ended 2025-12-31

$7.12M

Trailing 12 months to 2026-06-30

-39.7%

3-year compound annual growth

2022-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$22.50M	-50.6%	2026-02-18, From 2025-01-01
2024-12-31	$45.56M	+223.4%	2026-02-18, From 2024-01-01
2023-12-31	$14.09M	-86.3%	2026-02-18, From 2023-01-01
2022-12-31	$102.69M	n/a	2025-02-26, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	$22.50M	-50.6%
Alumis Inc. (ALMS)	2025-12-31	$24.05M	n/a
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	$20.71M	-27.4%
Scynexis Inc (SCYX)	2025-12-31	$20.60M	+449.9%
Evofem Biosciences, Inc. (EVFM)	2025-12-31	$20.18M	+4.2%
Entrada Therapeutics, Inc. (TRDA)	2025-12-31	$25.42M	-87.9%
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	$19.39M	+68.0%
Celularity Inc (CELU)	2025-12-31	$26.55M	-51.0%
Cue Biopharma, Inc. (CUE)	2025-12-31	$27.47M	+195.7%

Compare NAMS, ALMS, CASIF, SCYX side by side · Screen every company in Pharmaceutical Preparations ↗